Phase II trial of the histone deacetylase inhibitor romidepsin in patients with recurrent/metastatic head and neck cancer
Missak Haigentz(Albert Einstein College of Medicine), Robert I. Haddad(Georgetown University), Geoffrey I. Shapiro(Brigham and Women's Hospital), John M. Greally(Albert Einstein College of Medicine), B. Culliney(Mount Sinai Beth Israel), Roger Keresztes(Cornell University), Thomas J. Belbin(Albert Einstein College of Medicine), Lucian R. Chirieac(Mount Sinai Hospital), Mimi Kim(Albert Einstein College of Medicine), Juan Lin(Albert Einstein College of Medicine), Catherine Sarta(Albert Einstein College of Medicine), Richard V. Smith(Albert Einstein College of Medicine), Anu Gaba(Albert Einstein College of Medicine), John M. Mariadason(Olivia Newton-John Cancer Wellness & Research Centre)
Cited by 91
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
|New England Journal of Medicine|2007|1.7k
Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2022|1.4k
Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2020|1.4k
Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers
|Nature Medicine|2008|1.3k